Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Attenuation of neuro-inflammation improves survival and neurodegeneration in a mouse model of severe neonatal hyperbilirubinemia.

Vodret S, Bortolussi G, Iaconcig A, Martinelli E, Tiribelli C, Muro AF.

Brain Behav Immun. 2018 May;70:166-178. doi: 10.1016/j.bbi.2018.02.011. Epub 2018 Feb 16.

PMID:
29458193
2.

Alternatively spliced fibronectin extra domain A is required for hemangiogenic recovery upon bone marrow chemotherapy.

Malara A, Gruppi C, Celesti G, Abbonante V, Viarengo G, Laghi L, De Marco L, Muro AF, Balduini A.

Haematologica. 2018 Feb;103(2):e42-e45. doi: 10.3324/haematol.2017.173070. Epub 2017 Nov 16. No abstract available.

3.

Repeated AAV-mediated gene transfer by serotype switching enables long-lasting therapeutic levels of hUgt1a1 enzyme in a mouse model of Crigler-Najjar Syndrome Type I.

Bočkor L, Bortolussi G, Iaconcig A, Chiaruttini G, Tiribelli C, Giacca M, Benvenuti F, Zentilin L, Muro AF.

Gene Ther. 2017 Oct;24(10):649-660. doi: 10.1038/gt.2017.75. Epub 2017 Aug 14.

PMID:
28805798
4.

Promoterless gene targeting without nucleases rescues lethality of a Crigler-Najjar syndrome mouse model.

Porro F, Bortolussi G, Barzel A, De Caneva A, Iaconcig A, Vodret S, Zentilin L, Kay MA, Muro AF.

EMBO Mol Med. 2017 Oct;9(10):1346-1355. doi: 10.15252/emmm.201707601.

5.

Inflammatory signature of cerebellar neurodegeneration during neonatal hyperbilirubinemia in Ugt1 -/- mouse model.

Vodret S, Bortolussi G, Jašprová J, Vitek L, Muro AF.

J Neuroinflammation. 2017 Mar 24;14(1):64. doi: 10.1186/s12974-017-0838-1.

6.

Modulation of bilirubin neurotoxicity by the Abcb1 transporter in the Ugt1-/- lethal mouse model of neonatal hyperbilirubinemia.

Bockor L, Bortolussi G, Vodret S, Iaconcig A, Jašprová J, Zelenka J, Vitek L, Tiribelli C, Muro AF.

Hum Mol Genet. 2017 Jan 1;26(1):145-157. doi: 10.1093/hmg/ddw375.

PMID:
28025333
7.

Lack of Fibronectin Extra Domain A Alternative Splicing Exacerbates Endothelial Dysfunction in Diabetes.

Gortan Cappellari G, Barazzoni R, Cattin L, Muro AF, Zanetti M.

Sci Rep. 2016 Nov 29;6:37965. doi: 10.1038/srep37965.

8.

A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome.

Ronzitti G, Bortolussi G, van Dijk R, Collaud F, Charles S, Leborgne C, Vidal P, Martin S, Gjata B, Sola MS, van Wittenberghe L, Vignaud A, Veron P, Bosma PJ, Muro AF, Mingozzi F.

Mol Ther Methods Clin Dev. 2016 Jul 20;3:16049. eCollection 2016.

9.

Brief Report: Alternative Splicing of Extra Domain A (EIIIA) of Fibronectin Plays a Tissue-Specific Role in Hematopoietic Homeostasis.

Malara A, Gruppi C, Celesti G, Romano B, Laghi L, De Marco L, Muro AF, Balduini A.

Stem Cells. 2016 Aug;34(8):2263-8. doi: 10.1002/stem.2381. Epub 2016 May 4.

10.

Albumin administration prevents neurological damage and death in a mouse model of severe neonatal hyperbilirubinemia.

Vodret S, Bortolussi G, Schreuder AB, Jašprová J, Vitek L, Verkade HJ, Muro AF.

Sci Rep. 2015 Nov 6;5:16203. doi: 10.1038/srep16203.

11.

Impairment of enzymatic antioxidant defenses is associated with bilirubin-induced neuronal cell death in the cerebellum of Ugt1 KO mice.

Bortolussi G, Codarin E, Antoniali G, Vascotto C, Vodret S, Arena S, Cesaratto L, Scaloni A, Tell G, Muro AF.

Cell Death Dis. 2015 May 7;6:e1739. doi: 10.1038/cddis.2015.113.

12.

Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice.

Pulakazhi Venu VK, Uboldi P, Dhyani A, Patrini A, Baetta R, Ferri N, Corsini A, Muro AF, Catapano AL, Norata GD.

Thromb Haemost. 2015 Jul;114(1):186-97. doi: 10.1160/TH14-09-0790. Epub 2015 Apr 16.

PMID:
25881051
13.

TDP-43 regulates β-adducin (Add2) transcript stability.

Costessi L, Porro F, Iaconcig A, Muro AF.

RNA Biol. 2014;11(10):1280-90. doi: 10.1080/15476286.2014.996081.

14.

Generation of Ugt1-deficient murine liver cell lines using TALEN technology.

Porro F, Bockor L, De Caneva A, Bortolussi G, Muro AF.

PLoS One. 2014 Aug 13;9(8):e104816. doi: 10.1371/journal.pone.0104816. eCollection 2014.

15.

Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler-Najjar Syndrome.

Bortolussi G, Zentillin L, Vaníkova J, Bockor L, Bellarosa C, Mancarella A, Vianello E, Tiribelli C, Giacca M, Vitek L, Muro AF.

Hum Gene Ther. 2014 Sep;25(9):844-55. doi: 10.1089/hum.2013.233.

16.

Age-dependent pattern of cerebellar susceptibility to bilirubin neurotoxicity in vivo in mice.

Bortolussi G, Baj G, Vodret S, Viviani G, Bittolo T, Muro AF.

Dis Model Mech. 2014 Sep;7(9):1057-68. doi: 10.1242/dmm.016535. Epub 2014 Jul 25.

17.

EDA-containing fibronectin increases proliferation of embryonic stem cells.

Losino N, Waisman A, Solari C, Luzzani C, Espinosa DF, Sassone A, Muro AF, Miriuka S, Sevlever G, Barañao L, Guberman A.

PLoS One. 2013 Nov 14;8(11):e80681. doi: 10.1371/journal.pone.0080681. eCollection 2013.

18.

Characterization of the distal polyadenylation site of the ß-adducin (Add2) pre-mRNA.

Costessi L, Porro F, Iaconcig A, Nedeljkovic M, Muro AF.

PLoS One. 2013;8(3):e58879. doi: 10.1371/journal.pone.0058879. Epub 2013 Mar 15.

19.

Long-distance regulation of Add2 pre-mRNA3'end processing.

Nedeljkovic M, Costessi L, Iaconcig A, Porro F, Muro AF.

RNA Biol. 2013 Apr;10(4):516-27. doi: 10.4161/rna.23855. Epub 2013 Feb 14.

20.

Identification of 3' gene ends using transcriptional and genomic conservation across vertebrates.

Morgan M, Iaconcig A, Muro AF.

BMC Genomics. 2012 Dec 18;13:708. doi: 10.1186/1471-2164-13-708.

21.

Stam2 expression pattern during embryo development.

Curlin M, Kapuralin K, Muro AF, Baralle FE, Chowdhury K, Gajović S.

Gene Expr Patterns. 2012 Jan-Feb;12(1-2):68-76. doi: 10.1016/j.gep.2011.11.005. Epub 2011 Nov 28.

PMID:
22143071
22.

Rescue of bilirubin-induced neonatal lethality in a mouse model of Crigler-Najjar syndrome type I by AAV9-mediated gene transfer.

Bortolussi G, Zentilin L, Baj G, Giraudi P, Bellarosa C, Giacca M, Tiribelli C, Muro AF.

FASEB J. 2012 Mar;26(3):1052-63. doi: 10.1096/fj.11-195461. Epub 2011 Nov 17.

23.

Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis.

Booth AJ, Wood SC, Cornett AM, Dreffs AA, Lu G, Muro AF, White ES, Bishop DK.

J Pathol. 2012 Mar;226(4):609-18. doi: 10.1002/path.3010. Epub 2012 Jan 4.

24.

Fibronectin splice variants: understanding their multiple roles in health and disease using engineered mouse models.

White ES, Muro AF.

IUBMB Life. 2011 Jul;63(7):538-46. doi: 10.1002/iub.493. Review.

25.

The extra domain A of fibronectin is essential for allergen-induced airway fibrosis and hyperresponsiveness in mice.

Kohan M, Muro AF, Bader R, Berkman N.

J Allergy Clin Immunol. 2011 Feb;127(2):439-446.e1-5. doi: 10.1016/j.jaci.2010.10.021. Epub 2010 Dec 17.

PMID:
21167578
26.

CPEB2, CPEB3 and CPEB4 are coordinately regulated by miRNAs recognizing conserved binding sites in paralog positions of their 3'-UTRs.

Morgan M, Iaconcig A, Muro AF.

Nucleic Acids Res. 2010 Nov;38(21):7698-710. doi: 10.1093/nar/gkq635. Epub 2010 Jul 25.

27.

EDA-containing cellular fibronectin induces fibroblast differentiation through binding to alpha4beta7 integrin receptor and MAPK/Erk 1/2-dependent signaling.

Kohan M, Muro AF, White ES, Berkman N.

FASEB J. 2010 Nov;24(11):4503-12. doi: 10.1096/fj.10-154435. Epub 2010 Jul 19.

PMID:
20643910
28.

Control of fibroblast fibronectin expression and alternative splicing via the PI3K/Akt/mTOR pathway.

White ES, Sagana RL, Booth AJ, Yan M, Cornett AM, Bloomheart CA, Tsui JL, Wilke CA, Moore BB, Ritzenthaler JD, Roman J, Muro AF.

Exp Cell Res. 2010 Oct 1;316(16):2644-53. doi: 10.1016/j.yexcr.2010.06.028. Epub 2010 Jul 13.

29.

beta-adducin (Add2) KO mice show synaptic plasticity, motor coordination and behavioral deficits accompanied by changes in the expression and phosphorylation levels of the alpha- and gamma-adducin subunits.

Porro F, Rosato-Siri M, Leone E, Costessi L, Iaconcig A, Tongiorgi E, Muro AF.

Genes Brain Behav. 2010 Feb;9(1):84-96. doi: 10.1111/j.1601-183X.2009.00537.x. Epub 2009 Sep 22.

30.

Integrin-alpha9 is required for fibronectin matrix assembly during lymphatic valve morphogenesis.

Bazigou E, Xie S, Chen C, Weston A, Miura N, Sorokin L, Adams R, Muro AF, Sheppard D, Makinen T.

Dev Cell. 2009 Aug;17(2):175-86. doi: 10.1016/j.devcel.2009.06.017.

31.

New insights into form and function of fibronectin splice variants.

White ES, Baralle FE, Muro AF.

J Pathol. 2008 Sep;216(1):1-14. doi: 10.1002/path.2388. Review.

32.

An essential role for fibronectin extra type III domain A in pulmonary fibrosis.

Muro AF, Moretti FA, Moore BB, Yan M, Atrasz RG, Wilke CA, Flaherty KR, Martinez FJ, Tsui JL, Sheppard D, Baralle FE, Toews GB, White ES.

Am J Respir Crit Care Med. 2008 Mar 15;177(6):638-45. Epub 2007 Dec 20.

33.

Prothrombotic effects of fibronectin isoforms containing the EDA domain.

Chauhan AK, Kisucka J, Cozzi MR, Walsh MT, Moretti FA, Battiston M, Mazzucato M, De Marco L, Baralle FE, Wagner DD, Muro AF.

Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):296-301. Epub 2007 Nov 8.

PMID:
17991876
34.

Absence of regulated splicing of fibronectin EDA exon reduces atherosclerosis in mice.

Babaev VR, Porro F, Linton MF, Fazio S, Baralle FE, Muro AF.

Atherosclerosis. 2008 Apr;197(2):534-40. Epub 2007 Sep 27.

35.

A major fraction of fibronectin present in the extracellular matrix of tissues is plasma-derived.

Moretti FA, Chauhan AK, Iaconcig A, Porro F, Baralle FE, Muro AF.

J Biol Chem. 2007 Sep 21;282(38):28057-62. Epub 2007 Jul 19.

36.

Unexpected rescue of alpha-synuclein and multimerin1 deletion in C57BL/6JOlaHsd mice by beta-adducin knockout.

Gajović S, Mitrecić D, Augustincić L, Iaconcig A, Muro AF.

Transgenic Res. 2006 Apr;15(2):255-9.

PMID:
16604465
37.

Brain-specific promoter and polyadenylation sites of the beta-adducin pre-mRNA generate an unusually long 3'-UTR.

Costessi L, Devescovi G, Baralle FE, Muro AF.

Nucleic Acids Res. 2006 Jan 9;34(1):243-53. Print 2006.

38.

A polar mechanism coordinates different regions of alternative splicing within a single gene.

Fededa JP, Petrillo E, Gelfand MS, Neverov AD, Kadener S, Nogués G, Pelisch F, Baralle FE, Muro AF, Kornblihtt AR.

Mol Cell. 2005 Aug 5;19(3):393-404.

39.

Impaired motor coordination in mice lacking the EDA exon of the fibronectin gene.

Chauhan AK, Moretti FA, Iaconcig A, Baralle FE, Muro AF.

Behav Brain Res. 2005 Jun 3;161(1):31-8. Epub 2005 Apr 12.

PMID:
15904707
40.

The erythrocyte skeletons of beta-adducin deficient mice have altered levels of tropomyosin, tropomodulin and EcapZ.

Porro F, Costessi L, Marro ML, Baralle FE, Muro AF.

FEBS Lett. 2004 Oct 8;576(1-2):36-40.

41.

An exonic splicing enhancer offsets the atypical GU-rich 3' splice site of human apolipoprotein A-II exon 3.

Arrisi-Mercado P, Romano M, Muro AF, Baralle FE.

J Biol Chem. 2004 Sep 17;279(38):39331-9. Epub 2004 Jul 7.

42.

RNA folding affects the recruitment of SR proteins by mouse and human polypurinic enhancer elements in the fibronectin EDA exon.

Buratti E, Muro AF, Giombi M, Gherbassi D, Iaconcig A, Baralle FE.

Mol Cell Biol. 2004 Feb;24(3):1387-400.

44.

Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan.

Muro AF, Chauhan AK, Gajovic S, Iaconcig A, Porro F, Stanta G, Baralle FE.

J Cell Biol. 2003 Jul 7;162(1):149-60.

45.

Hypertension-linked decrease in the expression of brain gamma-adducin.

Yang H, Francis SC, Sellers K, DeBarros M, Sun C, Sumners C, Ferrario CM, Katovich MJ, Muro AF, Raizada MK.

Circ Res. 2002 Oct 4;91(7):633-9.

PMID:
12364392
46.

Hypertension in beta-adducin-deficient mice.

Marro ML, Scremin OU, Jordan MC, Huynh L, Porro F, Roos KP, Gajovic S, Baralle FE, Muro AF.

Hypertension. 2000 Sep;36(3):449-53.

PMID:
10988280
47.

Mild spherocytic hereditary elliptocytosis and altered levels of alpha- and gamma-adducins in beta-adducin-deficient mice.

Muro AF, Marro ML, Gajović S, Porro F, Luzzatto L, Baralle FE.

Blood. 2000 Jun 15;95(12):3978-85.

48.

Coupling of transcription with alternative splicing: RNA pol II promoters modulate SF2/ASF and 9G8 effects on an exonic splicing enhancer.

Cramer P, Cáceres JF, Cazalla D, Kadener S, Muro AF, Baralle FE, Kornblihtt AR.

Mol Cell. 1999 Aug;4(2):251-8.

49.

Involvement of fibronectin in the regulation of urokinase production and binding in murine mammary tumor cells.

Urtreger AJ, Aguirre Ghiso JA, Werbajh SE, Puricelli LI, Muro AF, Bal de Kier Joff E.

Int J Cancer. 1999 Aug 27;82(5):748-53.

50.

Regulation of fibronectin EDA exon alternative splicing: possible role of RNA secondary structure for enhancer display.

Muro AF, Caputi M, Pariyarath R, Pagani F, Buratti E, Baralle FE.

Mol Cell Biol. 1999 Apr;19(4):2657-71.

Supplemental Content

Support Center